Article Details
Retrieved on: 2024-08-19 14:29:56
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article describes PharmaDrug Inc.'s announcement of a Phase 1 clinical study for PD-001 by its biotech subsidiary Sairiyo Therapeutics. This highlights their forward-looking research focus on enhancing bioavailability of medications, including psychedelics, within the United States.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here